EGFR mutation and ALK rearrangement are meaningful targetable driver alterations in lung adenocarcinoma (LUAD) and non-small-cell lung cancer (NSCLC), respectively [26, 27]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.